What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• In 2023–mid‑2024 the FDA publicly moved against pharmacy‑compounded copies of GLP‑1 drugs (semaglutide, tirzepatide and similar products), saying many compounded GLP‑1 formulations were unapproved, potentially unsafe, and in many cases “essentially copies” of FDA‑approved drugs — so they should not be made and distributed outside the FDA approval process.
• The FDA issued warning letters and enforcement actions; many compounding shops stopped offering GLP‑1 compounds. That enforcement didn’t ban all compounding activity — it targeted pharmacies making non‑patient‑specific, essentially identical copies of brand biologics/approved drugs at scale.
• Who can still operate legally: compounding pharmacies that follow the law. In practice that means:
  • 503A (traditional) compounding pharmacies may legally compound a drug only when there is a valid, patient‑specific prescription and the product is not an unlawful copy of an FDA‑approved product.
  • 503B outsourcing facilities (if registered with FDA) may compound in bulk but must meet FDA’s current good manufacturing practices and cannot simply manufacture unapproved copies of approved biologics/drugs.
  • State boards of pharmacy also regulate compounding; some state rules are stricter than federal practice.

What the FDA’s concern was (brief)

• Safety and quality: compounded versions may lack the same manufacturing controls, sterility, dosing consistency and stability data as FDA‑approved products.
• Regulatory pathway: many compounded GLP‑1s were effectively copies of approved branded biologics (Wegovy/Ozempic, Mounjaro/Zepbound, etc.), and the FDA’s position is that such copies should go through the FDA approval/licensing process rather than be produced by compounding pharmacies.
• Public health risk: reports of adverse events, dosing errors and fraud tied to some online compounding sellers increased scrutiny.

How to tell if a pharmacy is operating legally now

• Ask the pharmacy:
  • Do you compound this product only with a patient‑specific prescription?
  • Are you a 503B outsourcing facility registered with the FDA (if making batches)?
  • Can you provide state pharmacy license details and evidence of sterility testing, lot records and COAs (certificate of analysis)?
• Check publicly:
  • FDA Warning Letters and Recalls page for any enforcement action against the business.
  • The FDA Outsourcing Facility List (for registered 503B firms).
  • Your state Board of Pharmacy for the pharmacy’s license status and any disciplinary history.
  • Independent verifiers: LegitScript and PharmacyChecker for online pharmacy reputations.

Safer alternatives

• Use FDA‑approved GLP‑1 products (manufacturer examples): Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). These are made under regulated manufacturing controls and prescribed by clinicians.
• Get GLP‑1s through licensed clinics, your regular prescriber, or reputable telehealth services that prescribe branded, FDA‑approved drugs and use accredited pharmacies to dispense them.

If you want, I can:

• Look up the current FDA warning‑letter status for a specific pharmacy or give step‑by‑step checks for one you’re considering (provide the pharmacy name and state).
  Note: I’m summarizing FDA actions and legal frameworks through mid‑2024; if you want the absolute latest enforcement actions I can walk you through where to check or help interpret a current FDA notice.